|
US5976790A
(en)
|
1992-03-04 |
1999-11-02 |
The Regents Of The University Of California |
Comparative Genomic Hybridization (CGH)
|
|
PT699237E
(pt)
|
1994-03-17 |
2003-07-31 |
Merck Patent Gmbh |
Fvs de cadeia anti-egfr e anticorpos anti-egfr
|
|
KR100737090B1
(ko)
|
2000-02-15 |
2007-07-06 |
아스텔라스세이야쿠 가부시키가이샤 |
축합 이미다졸륨 유도체
|
|
US7132511B2
(en)
|
2001-02-19 |
2006-11-07 |
Merck Patent Gmbh |
Modified anti-EGFR antibodies with reduced immunogenicity
|
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
CA2450285C
(en)
|
2001-06-13 |
2016-08-02 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (egfr)
|
|
MXPA05011078A
(es)
|
2003-04-15 |
2006-01-24 |
Astellas Pharma Inc |
Bromuro y sus cristales.
|
|
TW200526684A
(en)
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
|
WO2005094830A1
(en)
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
US20090253770A1
(en)
|
2004-05-18 |
2009-10-08 |
Kurume University |
Target gene mimitin of myc
|
|
JP2008514635A
(ja)
|
2004-09-27 |
2008-05-08 |
コーザン バイオサイエンシス インコーポレイテッド |
特異的キナーゼ阻害剤
|
|
DK1951759T3
(da)
|
2005-11-12 |
2010-05-10 |
Lilly Co Eli |
Anti-EGFR-antistoffer
|
|
JP4806776B2
(ja)
|
2006-01-27 |
2011-11-02 |
国立大学法人 千葉大学 |
ｃ−ｍｙｃ遺伝子転写抑制因子ＦＩＲのスプライシングバリアント又はイントロン２内の４塩基繰り返し配列による癌検出方法
|
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
諾華公司 |
吡咯并嘧啶化合物及其用途
|
|
US20100249413A1
(en)
|
2006-08-25 |
2010-09-30 |
Makoto Murai |
Stabilized pharmaceutical composition
|
|
JP5103604B2
(ja)
|
2006-10-31 |
2012-12-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド
|
|
US7618992B2
(en)
|
2006-12-29 |
2009-11-17 |
Astellas Pharma Inc. |
Method of treating cancer by co-administration of anticancer agents
|
|
EP2225235B1
(en)
|
2007-10-29 |
2017-09-06 |
Merck Sharp & Dohme Corp. |
Thiazole carboxamide derivatives and their use to treat cancer
|
|
ES2456966T3
(es)
|
2007-11-12 |
2014-04-24 |
Takeda Pharmaceutical Company Limited |
Inhibidores de MAPK/ERK cinasa
|
|
WO2009146034A2
(en)
|
2008-03-31 |
2009-12-03 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
ES2522346T3
(es)
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
WO2010056931A1
(en)
|
2008-11-14 |
2010-05-20 |
Intelligent Oncotherapeutics, Inc. |
Methods for identification of tumor phenotype and treatment
|
|
US8710068B2
(en)
|
2009-01-19 |
2014-04-29 |
The Trustees Of The University Of Pennsylvania |
Method of treating cancer using a survivin inhibitor
|
|
ES2576061T3
(es)
*
|
2010-02-25 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
|
|
EP2558092B1
(en)
|
2010-04-13 |
2018-06-27 |
Novartis AG |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
|
|
US8709419B2
(en)
*
|
2010-08-17 |
2014-04-29 |
Hoffmann-La Roche, Inc. |
Combination therapy
|
|
US20130004481A1
(en)
*
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
JP2014156400A
(ja)
|
2011-05-24 |
2014-08-28 |
Astellas Pharma Inc |
腫瘍の画像診断用標識誘導体
|
|
US20140228423A1
(en)
|
2011-06-01 |
2014-08-14 |
Baylor College Of Medicine |
Biomarkers and therapy for cancer
|
|
FI20115876A0
(fi)
|
2011-09-06 |
2011-09-06 |
Turun Yliopisto |
Yhdistelmähoito
|
|
US20130122005A1
(en)
*
|
2011-10-27 |
2013-05-16 |
Paul Adam |
Anticancer combination therapy
|
|
EP2780354A4
(en)
|
2011-11-16 |
2015-06-24 |
Oncomed Pharm Inc |
HUMAN NOTCH RECEPTOR MUTATIONS AND THEIR USE
|
|
US9662329B2
(en)
|
2012-03-26 |
2017-05-30 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of survivin antagonists in polyomavirus-related disease
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
PL2945628T3
(pl)
|
2013-01-15 |
2020-09-21 |
Aragon Pharmaceuticals, Inc. |
Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
|
|
US20160024591A1
(en)
|
2013-03-14 |
2016-01-28 |
Wake Forest University Health Sciences |
Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
|
|
MX2015010854A
(es)
|
2013-03-14 |
2016-07-20 |
Genentech Inc |
Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
|
|
SG11201507427QA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
MA38522A1
(fr)
|
2013-03-21 |
2017-10-31 |
Novartis Ag |
Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
|
|
US9314460B1
(en)
|
2013-04-09 |
2016-04-19 |
Stc.Unm |
Method for cancer cell reprogramming
|
|
KR101514877B1
(ko)
|
2013-05-06 |
2015-04-24 |
조선대학교산학협력단 |
ＡＰＥ/Ｒｅｆ -1 및 ＪＡＧ1/Ｎｏｔｃｈ의 대장암 진단용 마커로서의 용도
|
|
US20170080093A1
(en)
|
2013-10-22 |
2017-03-23 |
Tyme, Inc. |
Tyrosine Derivatives And Compositions Comprising Them
|
|
WO2015095840A1
(en)
|
2013-12-20 |
2015-06-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of cdk and erk inhibitors
|
|
US10668055B2
(en)
*
|
2013-12-20 |
2020-06-02 |
Biomed Valley Discoveries, Inc. |
Cancer treatment using combinations of ERK and RAF inhibitors
|
|
HUE055747T2
(hu)
|
2014-04-04 |
2021-12-28 |
Astrazeneca Ab |
EGFR-gátló és MEK-gátló kombinációja NRAS-mutált rák kezelésében történõ alkalmazásra
|
|
ES2823756T3
(es)
|
2014-04-16 |
2021-05-10 |
Signal Pharm Llc |
Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
|
|
EP3392348A3
(en)
|
2014-06-16 |
2018-11-21 |
Worldwide Innovative Network |
Method for selecting personalized tri-therapy for cancer treatment
|
|
US9446148B2
(en)
|
2014-10-06 |
2016-09-20 |
Mayo Foundation For Medical Education And Research |
Carrier-antibody compositions and methods of making and using the same
|
|
US9814714B2
(en)
|
2015-05-22 |
2017-11-14 |
Plexxikon Inc. |
Kinase modulation, and indications therefor
|
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
IL256242B2
(en)
|
2015-06-22 |
2024-09-01 |
Janssen Biotech Inc |
Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
|
|
US20170027951A1
(en)
*
|
2015-07-27 |
2017-02-02 |
Southern Research Institute |
Methods and compositions to treat cancers involving egfr
|
|
EP3340990B1
(en)
|
2015-08-28 |
2019-09-25 |
Novartis AG |
Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
|
|
US20170114098A1
(en)
|
2015-09-03 |
2017-04-27 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
US11499972B2
(en)
|
2015-09-15 |
2022-11-15 |
Swedish Health Services |
Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof
|
|
WO2017070475A1
(en)
|
2015-10-22 |
2017-04-27 |
Merrimack Pharmaceuticals, Inc. |
Methods of treating cancer by administering a mek inhibitor and a combination of anti-egfr antibodies
|
|
AU2017205478A1
(en)
|
2016-01-07 |
2018-06-28 |
Swadesh K. Das |
A method of modulating survival and stemness of cancer stem cells by MDA-9/Syntenin (SDCBP)
|
|
WO2017143237A1
(en)
|
2016-02-17 |
2017-08-24 |
Acetylon Pharmaceuticals, Inc. |
Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs
|
|
CN108289885B
(zh)
|
2016-09-23 |
2020-10-20 |
江苏恒瑞医药股份有限公司 |
酪氨酸激酶抑制剂在制备治疗癌症药物中的用途
|
|
WO2018127786A1
(en)
|
2017-01-06 |
2018-07-12 |
Oslo Universitetssykehus Hf |
Compositions and methods for determining a treatment course of action
|
|
CN106822905B
(zh)
|
2017-03-08 |
2019-05-17 |
暨南大学 |
含Survivin抑制剂和IRE1抑制剂的药物及用途
|
|
WO2018218633A1
(en)
*
|
2017-06-02 |
2018-12-06 |
Beijing Percans Oncology Co. Ltd. |
Combination therapies for treating cancers
|
|
US12571049B2
(en)
|
2018-03-21 |
2026-03-10 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes
|
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
|
CA3109605A1
(en)
|
2018-08-13 |
2020-02-20 |
Beijing Percans Oncology Co. Ltd. |
Biomarkers for cancer therapy
|
|
WO2020034061A1
(en)
|
2018-08-13 |
2020-02-20 |
Beijing Percans Oncology Co., Ltd. |
Biomarkers for cancer therapy
|
|
WO2020097901A1
(en)
|
2018-11-16 |
2020-05-22 |
Beijing Percans Oncology Co. Ltd. |
Biomarkers for cancer therapy
|